These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 31040439)

  • 21. New Hormonal Agents in Patients with Nonmetastatic Castration-resistant Prostate Cancer: Can We Be Satisfied with an Advantage in Metastasis-free Survival?
    Di Nunno V; Santoni M; Massari F
    Eur Urol Oncol; 2019 Jul; 2(4):471. PubMed ID: 31277785
    [No Abstract]   [Full Text] [Related]  

  • 22. Treatment of Primary in Metastatic Prostate Cancer: What Is the Standard of Care?
    Joseph N; Anjanappa M; Choudhury A
    Cancer J; 2020; 26(1):83-86. PubMed ID: 31977390
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The modern treatment of metastatic castration-resistant prostate cancer].
    Küronya Z; Biró K; Maráz A; Géczi L
    Magy Onkol; 2019 Mar; 63(1):41-50. PubMed ID: 30889620
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enzalutamide and Apalutamide: In Vitro Chemical Reactivity Studies and Activity in a Mouse Drug Allergy Model.
    Ji C; Guha M; Zhu X; Whritenour J; Hemkens M; Tse S; Walker GS; Evans E; Khan NK; Finkelstein MB; Callegari E; Obach RS
    Chem Res Toxicol; 2020 Jan; 33(1):211-222. PubMed ID: 31538772
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Evolving Systemic Treatment Landscape for Patients with Advanced Prostate Cancer.
    Pagliuca M; Buonerba C; Fizazi K; Di Lorenzo G
    Drugs; 2019 Mar; 79(4):381-400. PubMed ID: 30742279
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509.
    Joseph JD; Lu N; Qian J; Sensintaffar J; Shao G; Brigham D; Moon M; Maneval EC; Chen I; Darimont B; Hager JH
    Cancer Discov; 2013 Sep; 3(9):1020-9. PubMed ID: 23779130
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enzalutamide (Xtandi) for prostate cancer.
    Med Lett Drugs Ther; 2013 Mar; 55(1411):e20. PubMed ID: 23467121
    [No Abstract]   [Full Text] [Related]  

  • 28. New Antiandrogen Compounds Compared to Docetaxel for Metastatic Hormone Sensitive Prostate Cancer: Results from a Network Meta-Analysis.
    Marchioni M; Di Nicola M; Primiceri G; Novara G; Castellan P; Paul AK; Veccia A; Autorino R; Cindolo L; Schips L
    J Urol; 2020 Apr; 203(4):751-759. PubMed ID: 31689158
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Management of Anticoagulation in Patients With Prostate Cancer Receiving Enzalutamide.
    Shatzel JJ; Daughety MM; Olson SR; Beer TM; DeLoughery TG
    J Oncol Pract; 2017 Nov; 13(11):720-727. PubMed ID: 29125921
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Urological cancer: Enzalutamide in metastatic CRPC-old dog, new tricks.
    Tsao CK; Oh WK
    Nat Rev Clin Oncol; 2012 Nov; 9(11):613-4. PubMed ID: 23044775
    [No Abstract]   [Full Text] [Related]  

  • 31. [Effect and adverse event of enzalutamide and abiraterone in prostate cancer].
    Kosaka T; Oya M
    Nihon Rinsho; 2015 Feb; 73 Suppl 2():308-12. PubMed ID: 25831773
    [No Abstract]   [Full Text] [Related]  

  • 32. Targeting the androgen receptor.
    Friedlander TW; Ryan CJ
    Urol Clin North Am; 2012 Nov; 39(4):453-64. PubMed ID: 23084523
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increased Risk of Hypertension with Enzalutamide in Prostate Cancer: A Meta-Analysis.
    Zhu X; Wu S
    Cancer Invest; 2019; 37(9):478-488. PubMed ID: 31557062
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Validation of an LC-MS/MS method for simultaneous quantitation of enzalutamide, N-desmethylenzalutamide, apalutamide, darolutamide and ORM-15341 in mice plasma and its application to a mice pharmacokinetic study.
    Sulochana SP; Saini NK; Daram P; Polina SB; Mullangi R
    J Pharm Biomed Anal; 2018 Jul; 156():170-180. PubMed ID: 29709784
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Innovative Therapies to Overcome Resistance to Enzalutamide: Perspective on the Use of Darolutamide.
    Culig Z
    Eur Urol; 2018 Jan; 73(1):9-10. PubMed ID: 28890248
    [No Abstract]   [Full Text] [Related]  

  • 36. Enzalutamide and sleep apnea: an emerging central nervous system side-effect?
    Labrize F; Cany L; Massard C; Loriot Y; Sargos P; Gross-Goupil M; Roubaud G
    Ann Oncol; 2016 Jan; 27(1):206. PubMed ID: 26445811
    [No Abstract]   [Full Text] [Related]  

  • 37. Falsely Elevated Digoxin Levels in Patients on Enzalutamide.
    Kalra D; Tesfazghi M
    Circ Heart Fail; 2020 Jul; 13(7):e007008. PubMed ID: 32527146
    [No Abstract]   [Full Text] [Related]  

  • 38. [Management of enzalutamide, a new hormonal therapy].
    Beuzeboc P; Benderra MA; de La Motte Rouge T
    Bull Cancer; 2014 Jan; 101(1):107-12. PubMed ID: 24491670
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current understanding of resistance to abiraterone  and enzalutamide in advanced prostate cancer.
    Antonarakis ES
    Clin Adv Hematol Oncol; 2016 May; 14(5):316-9. PubMed ID: 27379691
    [No Abstract]   [Full Text] [Related]  

  • 40. Apalutamide: the established and emerging roles in the treatment of advanced prostate cancer.
    Dellis AE; Papatsoris AG
    Expert Opin Investig Drugs; 2018 Jun; 27(6):553-559. PubMed ID: 29856649
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.